THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;AMGEN, INC.;THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人:
ORAL, ELIF ARIOGLU,TAYLOR, SIMEON I,GARG, A.,DEPAOLI, ALEX M
申请号：
DK10165256
公开号：
DK2219031T3
申请日:
2002.10.22
申请国别(地区):
DK
年份:
2013
代理人:
摘要：
Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipodystrophy. Leptin is effective against lipodystrophy conditions for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including in a vector comprising nucleic acid sequences encoding leptin. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having approximately 4ng/ml or less before treatment.
